Navigation Links
Defiance III

ProductsDefiance III
Company DJO Incorporated
Item Defiance III
Features 
  • ACL/PCL versions with patented 4-point dynamic leverage system
  • Medial sweeping thigh that provides inner thigh clearance for bi-lateral brace use and riding sports
  • Anti-Migration Strap to prevent brace from migrating
  • Swiveling strap tabs for changing leg shapes through flexion and extension
  • Low profile hinge cover for better strength and medial clearance
  • Supra Condyle Suspension-prevents brace migration
  • Weighs approximately 18 ounces
  • Low-profile design
  • Custom made to individual patient measurements
  • 72-hour in-house turnaround
  • CI version with anterior thigh strap
  • Short calf version available for ski and motocross boot clearance
  • Short and standard lengths
  • Defiance Extra version includes reinforced carbon frame and slide shield
  • Suede, chamois and chamois pneumatic liners and strap pads available
  • Suede, chamois and chamois pneumatic liners and strap pads available Flexion stops: 45, 60, 75 and 90
  • Extension stops: 0, 10, 20, 30 and 40 (10 installed)
  • Easy to use custom measuring system (CCMI)
    • Description The Custom Defiance and Defiance III is DonJoy's hallmark knee brace. Combining the ultimate in technology, materials and design, this lightweight brace provides durable support for moderate to severe ACL, PCL, MCL and LCL instabilities. Plus, the low-profile design fits comfortably underneath clothing and sports uniforms, including hockey and football. As the strongest of DonJoy's functional braces, the custom, carbon composite Defiance is recommended for high collision sports, while its featherweight materials and custom fit also make it the brace of choice for activities of daily living. Available in three lengths: standard, short and standard thigh with short calf.Click here to view more on this featured product.
    Info DJO Incorporated
    Customer Service: (888) 624-5450
    Web site: http://www.djortho.com/

    Related medicine products :

    1. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 150)
    2. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Straight)
    3. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 90)
    4. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 135)
    5. Spanish Near Point Card
    6. Lebensohn Near Point Chart
    7. Contemporary Near Point Card
    8. Wormington Near Point Card
    9. Near Point Card 4 1/2 to 24 PT - BC2202
    10. Near Point Diagnostic Card Set - BC11982
    11. Near Point Card/Newspaper 8 to 48 - BC2203
    ...ecord streamlines patient information management a...ion. A flexible and easily customizable solution, ...ial benefits. HealthMatics EHR organizes communica... with outside practitioners. It also manages order...
    ...ded model EMR system designed for creating and sto...-line simultaneously. Designed by a multi-talented... engineers, meridianEMR combines the power of Java...at provides physicians with:, Our powerful EMR ...
    ..., ER/Trauma, ICC/CCU, woundcare and burn centers r..., plus consistent high quality for outstanding bar...rile Singles deliver all that and more. Their smoo...The gloves are powder-free with a special design t...
    ...s become even better. Polymed® TLC latex exami...Polymed with the exciting addition of vitamin E. V...are vital to healthy skin. Polymed TLC gloves are ...ential for latex sensitization. The lightly textur...
    Medicine Products:
    (Date:9/5/2008)...a nonprofit organization,devoted to improving publ...e launch of a new FDA Web site created to help the...er (DTC) advertising of prescription,medications. ...ising," is,hosted by the FDA,s Center for Drug Eva...in partnership with EthicAd. For details, visit, h...
    (Date:9/5/2008)...site shouldn,t overreact or stop taking them , ....S. Food and Drug Administration has started listi...tial safety issues, the agency said Friday. , ... we have begun analysis to determine whether there...ion," Dr. Gerald Dal Pan, director of the FDA,s Of...
    (Date:9/4/2008)...- A groundbreaking program,dealing with the deteri...en, their shorter life spans, unmet gender specifi...Wednesday, September 17 at White Plains,Hospital. ...estchester,medical and psychiatric societies will ...el Tiger, Ph.D., Dr. Legatto, an internationally ...
    (Date:9/4/2008)... shortchanging their golden years by tapping into ...y of Illinois expert who has studied the federal r... than three of every four Americans trim their mon...enefits early, a choice many might forego if they ...uences, law professor Richard L. Kaplan says. , ...
    Breaking Medicine News(10 mins):Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2Health News:FDA to List Drugs Under Review for Safety Issues 2Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3
    ...ne open-access journal PLoS Biology examines the r...p53. It has been found that any mutations of p53 p...ncers. //This particular study was carried out by ...provide a bit of background, when there a cell inj...
    ...ring encountered by men who underwent surgery for ...o underwent delayed surgeries and felt almost no s... pain felt by both categories were also reported t...n type of hernia, inguinal hernia, are either mini...
    ...s of death among the Americans. Nearly 500000 peop...recurrent attack of stroke. Though it has been a m...me drug that was discovered ten years ago. //There...t study on the treatment of stroke patients. Thee...
    ...der contract with the new Medicare drug plan have ...in a position to make 30 day supplies to all the p...patients // across the country were reportedly una...sed. It is also the responsibility of insurers to ...
    Other Medicine News:Health News:Need More And Better Drugs To Tackle Stoke 2Health News:Need More And Better Drugs To Tackle Stoke 3
    (Date:9/3/2008)...-,Pharmaceutical company Ph...hat it has enrolled the first subject into its sec...chitol in cystic fibrosis sufferers., The Phase 3...orth,America, Argentina and Germany, and is the fi...to market Bronchitol for cystic fibrosis in the,Un...
    (Date:9/3/2008)...chronically infected Hepatitis C,patients strongly... in 2008, - Study is the first to show a statist...effect of therapeutic Hepatitis C vaccination, -...a second generation, vaccine formulated with Inte... activation, VIENNA, Austr...
    (Date:9/3/2008)...dronedarone) decreased the risk of,stroke by 34% i...er already adequately treated by anti...RNewswire-FirstCall/ -- The results of a,post-hoc ...esented today at,the clinical trial update session...08, in Munich, Germany. Previous results from the ...
    (Date:9/3/2008)...osing Study in Subjects with ALS, RICHMOND, Calif...iences, Inc. (Nasdaq: SGMO ) announced today that...1) to evaluate its drug, SB-509, in subjects,with ...ase for which there,are limited treatment options ...table formulation of a plasmid,encoding a zinc fin...
    Breaking Medicine Technology:Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 2Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5International Expert Group Initiates Largest Multi center Phase III Trial to Evaluate NeuroAid 28TM 29 in Stroke Recovery 402 1International Expert Group Initiates Largest Multi center Phase III Trial to Evaluate NeuroAid 28TM 29 in Stroke Recovery 402 2International Expert Group Initiates Largest Multi center Phase III Trial to Evaluate NeuroAid 28TM 29 in Stroke Recovery 402 3International Expert Group Initiates Largest Multi center Phase III Trial to Evaluate NeuroAid 28TM 29 in Stroke Recovery 402 4Susan G Komen for the Cures Phoenix Affiliate State Officials Survivors and Advocates Call for Action on Breast Cancer 2194 1Susan G Komen for the Cures Phoenix Affiliate State Officials Survivors and Advocates Call for Action on Breast Cancer 2194 2Susan G Komen for the Cures Phoenix Affiliate State Officials Survivors and Advocates Call for Action on Breast Cancer 2194 3AISHealth com Introduces Three New Free Services 3A Health Business Daily Newsletter Health Business Meeting Calendar and Health Care Job Openings 2189 1AISHealth com Introduces Three New Free Services 3A Health Business Daily Newsletter Health Business Meeting Calendar and Health Care Job Openings 2189 2Genzyme Affirms Purchase Price for Bioenvision at 245 60 Per Outstanding Share 893 1Genzyme Affirms Purchase Price for Bioenvision at 245 60 Per Outstanding Share 893 2Genzyme Affirms Purchase Price for Bioenvision at 245 60 Per Outstanding Share 893 3
    ...men,learn about breast cancer therapy advances -- ...ew,GfK Roper Public Affairs survey sponsored by Ca...nization, while the majority (76,percent) of women...out breast cancer, many remain unaware of the impo...n one out of four (23 percent),women ages 50-65 ha...
    ...heumatoid arthritis (RA) have ushered in a new era...condition. The findings are,reported in a New Drug...ming edition of The Lancet. , RA is the most commo...cting 0·5–1% of the,population in the...int pain, stiffness, and swelling due to synovial ...
    Other Medicine Technology:Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 2Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 3